Close Menu

NEW YORK (GenomeWeb) – Merck KGaA and Sysmex Inostics are planning to set up additional test sites for the OncoBEAM RAS CRC liquid biopsy diagnostic in Asia and South America.

The two firms began developing the RAS mutation panel following a 2014 deal. The test is based on Sysmex's emulsion-based digital PCR technology, called BEAMing, which stands for beads, emulsions, amplification, and magnetics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul
25
Sponsored by
Roche

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Aug
22
Sponsored by
BC Platforms

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.